Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
leflunomide
Teva Pharma B.V.
L04AA13
leflunomide
Immunosuppressants
Arthritis, Rheumatoid
Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.
Revision: 6
Withdrawn
2011-03-10
53 B. PACKAGE LEAFLET Medicinal product no longer authorised 54 PACKAGE LEAFLET: INFORMATION FOR THE USER LEFLUNOMIDE TEVA 10 MG FILM-COATED TABLETS leflunomide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects , talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET 1. What Leflunomide Teva is and what it is used for 2. What you need to know before you take Leflunomide Teva 3. How to take Leflunomide Teva 4. Possible side effects 5. How to store Leflunomide Teva 6. Contents of the pack and other information 1. WHAT LEFLUNOAMIDE TEVA IS AND WHAT IT IS USED FOR Leflunomide Teva belongs to a group of medicines called anti-rheumatic medicines. It contains the active substance leflunomide. Leflunomide Teva is used to treat adult patients with active rheumatoid arthritis. Rheumatoid arthritis is a crippling form of arthritis. The symptoms include inflammation of joints, swelling, difficulty moving and pain. Other symptoms that affect the entire body include loss of appetite, fever, loss of energy and anemia (lack of red blood cells). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LEFLUNOAMIDE TEVA DO NOT TAKE LEFLUNOMIDE TEVA - If you are ALLERGIC to leflunomide (especially a serious skin reaction, often with fever, joint pain, red skin stains, or blisters e.g. Stevens-Johnson syndrome) or any of the other ingredients of this medicine (listed in section 6). - If you have LIVER PROBLEMS . - If you suffer from a severe condition that affects your IMMUNE SYSTEM e.g. AIDS. - If you have BONE MARROW PROBLEMS , or if you have low numbers of red or white blood cells or a reduced Aqra d-dokument sħiħ
1 _ _ _ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Leflunomide Teva 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of leflunomide. _Excipients with known effect: _ Each tablet contains 97.25 mg of lactose monohydrate and 3.125 mg anhydrous lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. White, round film-coated tablets, engraved with “10” on one side and “L” on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a "disease modifying antirheumatic drug" (DMARD). Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit/risk aspects. Moreover, switching from leflunomide to another DMARD without following the washout procedure (see section 4.4) may also increase the risk of serious adverse reactions even for a long time after the switching. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The treatment should be initiated and supervised by specialists experienced in the treatment of rheumatoid arthritis. Alanine aminotransferase (ALT) or serum glutamopyruvate transferase (SGPT) and a complete blood cell count, including a differential white blood cell count and a platelet count, must be checked simultaneously and with the same frequency: • before initiation of leflunomide, • every two weeks during the first six months of treatment, and • every 8 weeks thereafter (see section 4.4). _Posology _ Medicinal product no longer authorised 3 • In rheumatoid arthritis: leflunomide therapy is usually started with a loading dose of 100 mg once daily for 3 days. Omission of the loading dose may decrease the risk of adverse event Aqra d-dokument sħiħ